Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Capricor Therapeutics, Inc. (CAPR)

4.07   -0.06 (-1.45%) 11-25 13:00
Open: 4.19 Pre. Close: 4.13
High: 4.19 Low: 4.01
Volume: 48,833 Market Cap: 103(M)

Technical analysis

as of: 2022-11-25 1:55:47 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 6.18     One year: 7.22
Support: Support1: 3.84    Support2: 3.2
Resistance: Resistance1: 5.29    Resistance2: 6.19
Pivot: 4.36
Moving Average: MA(5): 4.07     MA(20): 4.61
MA(100): 5.23     MA(250): 4.29
MACD: MACD(12,26): -0.5     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 16.2     %D(3): 14.5
RSI: RSI(14): 31.3
52-week: High: 6.57  Low: 2.55
Average Vol(K): 3-Month: 182 (K)  10-Days: 143 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CAPR ] has closed above bottom band by 31.6%. Bollinger Bands are 36.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.2 - 4.22 4.22 - 4.24
Low: 4.06 - 4.08 4.08 - 4.1
Close: 4.09 - 4.13 4.13 - 4.16

Company Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Headline News

Sat, 26 Nov 2022
Top Industrial IT Services Stocks You Can Buy Today - Best Stocks

Wed, 16 Nov 2022
Capricor Therapeutics Third Quarter 2022 Earnings: Beats Expectations - Simply Wall St

Fri, 11 Nov 2022
Capricor Therapeutics Earnings, Revenue Beat in Q3 By Investing.com - Investing.com

Thu, 10 Nov 2022
Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript - Seeking Alpha

Thu, 10 Nov 2022
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq

Thu, 03 Nov 2022
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 25 (M)
% Held by Insiders 2.403e+007 (%)
% Held by Institutions 2.6 (%)
Shares Short 331 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.76e+007
EPS Est Next Qtl -0.19
EPS Est This Year -0.7
EPS Est Next Year -0.76
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 759.9
Return on Equity (ttm) -36.1
Qtrly Rev. Growth 1.59e+006
Gross Profit (p.s.) 0
Sales Per Share -24.63
EBITDA (p.s.) -3.11449e+006
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.17
Price to Cash Flow 28.09

Stock Dividends

Dividend 0
Forward Dividend 247510
Dividend Yield 0%
Dividend Pay Date 2019-06-04
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.